CSPAN Key Capitol Hill Hearings March 28, 2015
We are seeing both development and review times decreased significantly with exciting new therapies entering the marketplace much sooner for the patients who need them. Last year we approve the most new drugs in almost 20 years. And more orphan drugs than ever before. 41 of these new drugs were first in class products, resulting in a breathtaking array of truly Innovative New therapies for patients, and the majority of these new drugs were approved using some kind of expedited pathway. Today, contrary to what many would say, fda approved drugs faster on average than all other advanced nations,...